FDA approves SPRINT endura (single lead) and extensa (dual lead) peripheral nerve stimulation (PNS) systems.- SPR Therapeutics.

SPR Therapeutics, Inc., a leader in neurostimulation technology for pain, announced that the FDA has cleared its SPRINT endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation (PNS) Systems. The SPRINT System is the only percutaneous PNS System cleared by the FDA and indicated for up to 60 days in the back and/or extremities for both chronic and acute pain and is the industry's only dual lead capable PNS platform.

Comment: The devices are minimally invasive alternatives to opioids that are implanted for up to 60 days to relieve acute and chronic pain, including post-traumatic and post-operative pain. The components are removed after treatment. The SPRINT PNS System leads are placed by a physician during an outpatient procedure without surgery, incisions, tissue destruction or anesthesia offering a minimally invasive and non-opioid 60-day therapy. SPRINT has demonstrated significant and sustained pain relief across multiple studies.